Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH


2.5 | PUBLIKATIONEN


Die Ergebnisse unserer Forschungsaktivitäten publizieren wir in internationalen Fachzeitschriften und auf wissenschaftlichen Kongressen der amerikanischen und europäischen Pneumologenvereinigungen. Datenbank-gelistete Publikationen finden Sie hier unter PubMed

Eine Liste der seit 2014 publizierten Kongressbeiträge ist im Folgenden aufgeführt. Eine vollständige Lister aller publizierten Kongressbeiträge kann jederzeit unter angefordert werden.

1. Holz O, Roepcke S, Watz H, Lahu JM, Hohlfeld J (2014) Effect of exercise challenge on systemic inflammatory markers in healthy smokers and smokers with COPD. Eur Respir J 44: Suppl. 58, 4889.

2. Mesquita R, Pitta F, Donaire-Gonzalez D, Deering BM, Patel M, Mitchell KE, Alison J, van Gestel AJR, Zogg S, Garcia-Aymerich J, Hill K, Romme E, Kon S, Albert P, Waschki B, Shrikrishna D, Singh SJ, Hopkinson NS, Miedinger D, Jenkins C, Polkey MI, Jenkins SC, Man WDC, Clarenbach CF, Hernandes NA, Hillman HR, Furlanetto KC, McKeough Z, Watts S, Cindy Ng, Brooks D, Eastwood PR, Sant'Anna T, Meijer K, Dürr S, Kohler M, Probst VS, Tal-Singer R, Leuppi JD, Calverley PMA, Smeenk W, Yates J, Costello RW, Goldstein R, Magnussen H, Wouters EFM, ZuWallack R, Watz H, Spruit MA (2014) Objective moderate-to-vigorous physical activity in 1064 patients with COPD after stratification for gender, FEV1 and BMI. Eur Respir J 44: Suppl. 58, 1981.

3. Esser RW, Stoeckel MC, Kirsten A, Watz H, Lehmann K, Taube K, Magnussen H, Büchel C, von Leupoldt A (2014) Structural brain changes in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 44: Suppl. 58, 646.

4. Maltais F, Iturri JBG, Kirsten A, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R (2014) Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Eur Respir J 44 Supp 58: P283.

5. Magnussen H, Chanez P, Dahl R, Decramer M, Disse B, Finnigan H, Kirsten A, Rodriguez-Roisin R, Tetzlaff K, Towse L, Watz H, Wouters E, Calverley PMA (2014) The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study. Eur Respir J 44: Suppl. 58, 1890.

6. Buhl R, Derom E, Ferguson G, Maltais F, Pizzichini E, Reid J, Watz H, Groenke L, Hamilton A, Tetzlaff K, Korducki L, Huisman H, Waitere-Wijker S, Bateman E (2014) Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies. Eur Respir J 44: Suppl. 58, 1895.

7. Pedersen F, Lauer G, Quintini G, Holz O, Kirsten AM, Magnussen H, Rabe KF, Goldmann T, Watz H (2014) Multi-analyte profiling of inflammatory markers in COPD sputum. Eur Respir J 44: Suppl. 58, 837.

8. Watz H, Calverley P, Chanez P, Dahl R, Decramer M, Disse B, Finnigan H, Kirsten A, Rodriguez-Roisin R, Tetzlaff K, Towse L, Wouters E, Magnussen H (2014) The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study. Eur Respir J 44: Suppl. 58, 2423.

9. Nagelschmitz J, Kaufel D, Stephan S, von Nussbaum F, Delbeck V, Lustig K, Bandel T, Watz H (2014) The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases. Eur Respir J 44: Suppl. 58, 3416.

10. Watz H, Nagelschmitz J, Pedersen F, Ringshausen FC, Kirsten A, Magnussen H, Rabe KF, Welte T, Rademacher J, Rentzsch C, Schumann C, Zubov D, Schäfer S, Schwers S (2014) Conduct of a biomarker study in bronchiectasis patients: Correlation of neutrophil elastase activity and inflammatory load in induced sputum. Eur Respir J 44: Suppl. 58, 2049.

11. Seehase S, Watz H, Kugler C, Vollmer E, Goldmann T (2014) Surfactant protein expression at various COPD Gold stages. Eur Respir J 44: Suppl. 58, 3994.

12. Garn H, Krug N, Hohlfeld J, Kirsten AM, Kornmann O, Beeh K, Dappeler D, Korn S, Ignatenko S, Rogon C, Bille J, Homburg U, Turowska A, Buhl R, Renz J, Renz H (2014) Attenuation of allergen-induced asthmatic responses by inhaled GATA-3-specific DNAzyme. Eur Respir J 44 Supp 58: P2816.

13. Richeldi L, Kirsten AM, Roman J, LeMaulf F, Hallmann C, Stowasser S, Lasky JA. (2014) Poolded analysis of mortality data from the TOMORROW and INPULSIS trials of nintedanib in idiopathic pumonary fibrosis (IPF). ICLAF.

14. Holz O, Müller M, Ignatenko S, Kappeler D, Buhl R, Beeh KM, Kornmann O, Kirsten A, Homburg U, Garn H, Krug N, Hohlfeld JM (2014) Effect Of Sample Processing On The Analysis Of IL4, IL5, And IL13 In Sputum Supernatants Am J Respir Crit Care Med 189: A 4255.

15. Kirsten AM, Maltais F, Hamilton A, DeSousa D, Wang F, Decramer M (2014) Beurteilung der Wirkung von Olodaterol auf die Ausdauerbelastungsfähigkeit bei COPD Patienten: Ergebnisse aus zwei sechswöchigen Studien. Der Internist 55: P051.

16. Maltais F, Galdiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R (2014) Effects of 12 weeks of once-daily Tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Thorax 69: P250.

17. Kirsten AM, Richard A, Tanase AM, Weihua C, Hosoe M, Hederer B (2014) Efficacy and safety of once-daily indacaterol/mometasone compared with twice-daily salmeterol/fluticasone in patients with moderate to very severe COPD. Thorax 69: P P251.

18. Maltais F, Iturri JBG, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R (2015) Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD Pneumologie 69: P77.

19. Kirsten AM, Richeldi L, Roman J, LeMaulf F, Hallmann C, Stowasser S, Lasky JA (2015) Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF) Pneumologie 69: P24.

20. Kirsten AM, Richard A, Tanase A-M, Weihua C, Hosoe M, Hederer B (2015) Wirksamkeit und Sicherheit von Indacaterol/Mometason verglichen mit Salmeterol/Fluticason bei Patienten mit mäßiger bis schwerer COPD. Pneumologie 69: P55.

21. Maltais F, Kirsten A, Hamilton A, De Sousa D, Voß F, Decramer M (2015) The Influence of Log Transformation in Analyzing Exercise Endurance Time Data in COPD: Results from Two Olodaterol Trials. Am J Respir Crit Care Med 191: A5737.

22. O'Donnell D, Casaburi, R, De Sousa D, Xue W, Frith P, Hamilton A, Kirsten A, Maltais F (2015) Effects of 6 Weeks' Treatment with Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination on Inspiratory Capacity and Exercise Endurance in Patients with COPD: The MORACTO™ Studies. Am J Respir Crit Care Med 191: A3972.

23. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Seoane B, Segarra RM, Leselbaum A, Garcia Gil E (2015) The Efficacy and Safety of Aclidinium/Formoterol Fixed-Dose Combination Compared with Salmeterol/Fluticasone in Patients with COPD: Results from a Phase III Study. Am J Respir Crit Care Med 191: A3974.

24. Watz H, Ferguson G, Gronke L, Vob F, Abrahams R, Buhl R (2015) Inhaled Corticosteroid Plus Long-Acting β2-Agonist Therapy is Overused in the Treatment of Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analyses of Two 1-Year Studies. Am J Respir Crit Care Med 191: A5784.

25. Watz H, Bateman ED, Magnussen H, Kirsten A, Tetzlaff K, Disse B, Finnigan H, Calverley PM, Rodriguez-Roisin R (2015) Stepwise Withdrawal of Inhaled Corticosteroids in COPD Patients Receiving Dual Bronchodilators: Lung Function Reduction in the WISDOM Study. Am J Respir Crit Care Med 191: A3641.

26. Magnussen H, Bateman ED, Watz H, Kirsten A, Tetzlaff K, Disse B, Finnigan H, Rodriguez-Roisin R, Calverley PM (2015) High Level of Agreement Between Home-Based and In-Clinic Spirometry Results in the WISDOM COPD Study. Am J Respir Crit Care Med 191: A5806.

27. Watz H, Wilke S, Bals R, Karch A, Koch A, Schulz H, Welte T, Vogelmeier C, Jorres RA (2015) Prevalence of Peripheral Artery Disease in Patients with Chronic Obstructive Pulmonary Disease: Results of the COSYCONET Study. Am J Respir Crit Care Med 191: A5710.

28. Wilke S, Watz H, Bals R, Franssen F, Holle R, Karch A, Koch A, Schulz H, Spruit, MA, Wacker ME, Welte T, Wouters EFM, Jorres RA, Vogelmeier C (2015) Impact of Peripheral Artery Disease on Functional Capacity and Health Status in Patients with Chronic Obstructive Pulmonary Disease: Results of the COSYCONET Study. Am J Respir Crit Care Med 191: A6204.

29. Jorres RA, Biertz F, Vogel C, Kauczor HU, Biederer J, Jobst B, Heinrich J, Koch A, Watz H, Welte T, Vogelmeier C (2015) Prediction of Emphysema from Lung Function Parameters and Chest CT Scans Obtained in Clinical Routine: Results of the German COSYCONET Study. Am J Respir Crit Care Med 191: A2257.

30. Bateman ED, Rodriguez-Roisin R, Calverley PM, Tetzlaff K, Disse B, Finnigan H, Magnussen H, Watz H (2015) Withdrawal of Inhaled Corticosteroids and Exacerbations of COPD: The WISDOM Phenotyping Substudy. Am J Respir Crit Care Med 191: A3979.

31. Watz H, Mailaender C, Kirsten AM (2015) Superiority of Glycopyrronium versus Tiotropium in Early Onset of Bronchodilation in Patients with Moderate to Severe COPD - The FAST Study. Am J Respir Crit Care Med 191:A5763.

32. Wacker M E, Wilke S, Karch A, Schulz H, Watz H, Jörres R A, Vogelmeier C, Holle R (2015) Assessing health-related quality of life in COPD: A comparison between one generic and two disease-specific instruments. Eur Respir J 46 Suppl. 59 PA5074.

33. Jörres R A, Biertz F, Vogel C, Kauczor H-U, Biederer J, Jobst B, Heinrich J, Koch A, Watz H, Welte T, Vogelmeier C (2015) Chest CT scans obtained in multicentre clinical routine assessments are sufficient to develop a prediction function for emphysema from lung function. Eur Respir J 46 Suppl. 59, OA4986.

34. Rabe K, Martinez F, Rodriguez-Roisin R, Fabbri L M, Ferguson G T, Jones P, Rennard S, Golden M, Darken P, Orevillo C, Fischer T, Reisner C (2015) PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. Eur Respir J 46 Suppl. 59, PA4363.

35. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten A-M, Seoane B, Segarra RM, Leselbaum A, Garcia Gil E (2015) Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD. Eur Respir J 46 Suppl. 59, PA2960.

36. Annoni R, Couceiro L, Barbosa S, Lancas T, Battaglia S, Dolhnikoff M, Hiemstra P, Ster P, Rabe K, Mauad T (2015). Versican and collagen-III expression in bronchial and pulmonary muscular arteries in COPD patients. Eur Respir J 46 Suppl. 59, PA2446.

37. Martinez F J, Calverley P M A, Goehring U-M, Hodge R, Fabbri L M, Rabe K F (2015) Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy. Eur Respir J 46 Suppl. 59, OA482.

38. Esser R W, Stoeckel M C, Kirsten A, Watz H, Lehmann K, Taube K, Büchel C, Magnussen H, Leupoldt Von A (2015) Neural correlates of dyspnea in COPD. Eur Respir J 46 Suppl. 59, OA4954.

39. Waschki B, Kirsten A, Holz O, Müller K-C, Schaper M, Sack A-L, Meyer T, Rabe K, Magnussen H, Watz H (2015) The role of sustained inactivity in the progression of exercise intolerance and muscle depletion in COPD. Eur Respir J 46 Suppl. 59, PA3550.

40. Wilke S, Bals R, Franssen F, Karch A, Koch A, Schulz H, Spruit M, Welte T, Wouters E, Jörres R, Vogelmeier C, Watz H (2015) Impact of peripheral artery disease on functional capacity in patients with COPD: Results of the COSYCONET study. Eur Respir J 46 Suppl. 59, PA2069.

41. Watz H, Magnussen H, Kirsten A, Tetzlaff K, Finnigan H, Disse B, Batemann E (2015) Lung Function change and exacerbations in patients with COPD in the WISDOM study. Eur Respir J 46 Suppl. 59, PA1019.

42. Alter P, Karch A, Watz H, Koch A, Welte T, Schulz H, Jörres R, Vogelmeier C (2015) COPD is associated with left ventricular size and function: Results from COSYCONET. Eur Respir J 46 Suppl. 59, PA613.

43. Pedersen F, Marwitz S, Goldmann T, Kirsten A, Magnussen H, Rabe KF, Uddin M, Watz H (2015) Enhanced neutrophil extracellular trap (NET) formation in sputum of stable COPD patients. Eur Respir J 46 Suppl. 59, PA379.

44.Watz H, Calverley P, Chanez P, Dahl R, Decramer MLA, Disse B, Finnigan H, Kirsten AM, Rodriguez-Roisin R, Tetzlaff K, Towse L, Wouters E, Magnussen H (2015) The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Pneumologie 69: P67.

45. Magnussen H Chanez P, Dahl R, Decramer MLA, Disse B, FinniganH, Kirsten AM, Rodriguez-Roisin R, Tetzlaff K, Towse L, Watz H, Wouters E, Calverley P (2015) The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Pneumologie 69: P75.

46. Kirsten AM, Watz H, Kirsten D (2015) Lymphangioleiomyomatose und Pneumothoraxrisiko beim Fliegen. Pneumologie 69: P488.

47. Watz H, Magnussen H, Rodriguez-Roisin, R, Wouters E, Disse B, Tetzlaff K, Finnigan H, Calverley P (2015) Subgroup Analyses of Lung-Function Change from the WISDOM Study. Chest 148: 755A.

48. Watz H, Mailänder C, Kirsten AM (2015) Superiority of glycopyrronium versus tiotropium in early onset of bronchodilation in patients with moderate to severe COPD- the FAST study. Thorax 70: A140.

49. Watz H, Mailänder C, Kirsten A (2015) Effects of indacaterol/glycopyrronium on lung function and physical activity in patients with moderate to severe COPD. Thorax 70: A146.

50. Watz H, Ferguson GT, Grönke L, Voss F, Abrahams R, Buhl R (2015) Inhaled corticosteroid plus long-acting ß2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: post hoc analyses of two 1-year studies. Thorax 70: A137.

51. Watz H, Derom E, Korn S, Hamilton A, Amatto VC, Zhao Y, Maltais F (2016) Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on beta-blockers. 57. Pneumologie 70: P426.

52. Watz H, Mailänder C, Kirsten AM (2016) Effekte von Indacaterol/Glycopyrronium auf Lungenfunktion und die gemessene körperliche Aktivität von Patienten mit moderater bis schwerer COPD. 57. Pneumologie 70: P205.

53. Watz H, Kalberg C, Brooks J, Worsley S, Harris S, Zvarich M, Church A (2016) Wirkungseintritt von Umeclidinium/Vilanterol im Vergleich zu anderen Erhaltungstherapien bei Patienten mit COPD. 57. Pneumologie 70: P321.

54. Watz H, Ferguson GT, Grönke L, Voss F, Abrahams, R, Buhl R (2016) Inhaled corticosteroid plus long-acting beta2-agonist therapy is overused in the treatment of patients with Chronic Obstructive Pulmonary Disease: Post hoc analyses of two 1-year studies. Pneumologie 70: P247.

55. Watz H, Mailänder C, Kirsten AM (2016) Überlegenheit von Glycopyrronium im Vergleich zu Tiotropium in der früh-einsetzenden Bronchodilatation von Patienten mit moderater bis schwerer COPD - Die FAST Studie. Pneumologie 70: P197.

56. Bahmer T, Watz H, Waschki B, Gramm M, Magnussen H, Rabe KF, Wirtz H, Kirsten D, Kirsten AM (2016) Körperliche Aktivität und der Einfluss von Atemwegsobstruktion, Gesundheitsstatus und Fatigue bei Patienten mit Lymphangioleiomyomatose. Pneumologie 70: P557.

57. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Seoane B, Segarra RM, Leselbaum A, GarciaGil E (2016) Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD. Pneumologie 70: P364.

58. Richeldi, L, Selman M, Kirsten AM, Wuyts WA, Bernoids K, Stowasser S, Quaresma M, Costabel U (2016) Long-term efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the TOMORROW trial and its open-label extension, ICLAF 2016 JQM 109 suppl1 DOI:http://dx.doi.org/10.1093/qjmed/hcw127.006.

59. Alter P, Watz H, Welte T, Glaser S, Schulz H, Bals R, Sohler S, Karch A, Vogelmeier C, Jörres RA (2016) Spirometric and bodyplethysmographiclLung function is associated with echocardiography-derived ventricular wall stress in COPD. Am J Respir Crit Care Med 2016: A2988.

60. Beier J, Mroz Ro, Kirsten AM, Garcia Gill FCE (2016) Improvement in lung function and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post-hoc analysis of a Phase IIIb study Am J Respir Crit Care Med 2016 A: 6817.

61. Waschki B, Kirsten AM, Holz O, Meyer T, Lichtinghagen R, Rabe KF, Magnussen H, Welte T, Watz H, Janciauskiene S (2016) α1-Antitrypsin (A1AT) serum levels as marker of systemic inflammation in non-A1AT-deficient patients with COPD. Am J Respir Crit Care Med 2016: A3488.

62. Watz H, Magnussen H, Tetzlaff K, Gronke L, Finnigang H, Calverley PM (2016) Is blood eosinophil count a predictor of disease worsening after ICS withdrawal? Am J Respir Crit Care Med 2016: A6234.

63. Magnussen H, Arzt M, Andreas S, Plate T, Ribera A, Seoane B, Watz H, Kirsten AM (2016) The effect of aclidinium bromide 400 µg on lung function, sleep quality and physical activity in patients with Chronic Obstructive Pulmonary Disease: Results of a phase IV pilot study. Am J Respir Crit Care Med: A6820.

64. Jutta Beier, Robert Mroz, Anne-Marie Kirsten, Ferran Chuecos Esther Garcia GilI (2016) Improvement in lung function and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post-hoc analysis of a Phase IIIb study Am J Respir Crit Care Med 2016A: 6817.

65. Vogelmeier C, Fabbri LM, Bell S, Tetzlaff, K, Magnussen, Watz H (2016).Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study. Eur Respir J;48:Suppl.60 PA302.

66. Watz H, Bagul N, Nip K, Sun K, Goehring U, Calverley P, Rabe KF (2016). Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE). Eur Respir J;48:Suppl.60 PA308.

67. Miller B, Tal-Singer R, Lazaar A, Leidy N, Watz H, Collins D, Yonchuk J, Tabberer M (2016). Assessing symptoms in COPD: Use of the E-RS daily digital diary in early drug development. Eur Respir J;48:Suppl.60 PA1047.

68. Wacker ME, Jörres RA, Karch A, Wilke S, Heinrich J, Karrasch S, Koch A, Schulz H, Watz H, Leidl R, Vogelmeier C, Holle R (2016). Can disease-specific questionnaires describe the effect of comorbidities on health-related quality of life in patients with COPD? A comparison of disease-specific and generic questionnaires in the COSYCONET cohort. Eur Respir J;48:Suppl.60 PA1150.

69. Karrasch S, Schäfer J, Kiehl G, Lucke T, Sußmann M, Luzak A, Ochmann U, Nowak D, Jörres RA, Vogelmeier C, Watz H, Schulz H, COSYCONET Study Group (2016) Comparison of physical activity measures assessed by two different accelerometers in COPD patients. Eur Respir J;48:Suppl.60 PA1154.

70. Bahmer T, Kirsten A, Schatz F, Herzmann C, Waschki B, Rabe KF, Watz H (2016) Physical activity in patients with asthma. Eur Respir J;48:Suppl.60 PA1578.

71. Calverley MA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters E, Disse B, Finnigan H, Asijee GM, Watz H (2016) LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD. Eur Respir J;48:Suppl.60 OA1973.

72. Waschki B, Kirsten A, Holz O, Meyer T, Lichtinghagen R, Rabe KF, Magnussen H, Welte T, Watz H, Janciauskiene S (2016) Association of angiopoietin-like protein 4 with cardiovascular function in patients with COPD. Eur Respir J;48:Suppl.60 OA3004.

73. Fähndrich S, Biertz F, Watz H, Welte T, Karch A, Koch A, Kauczor HU, Jörres RA, Vogelmeier C, Bals R (2016) Differences in the disease phenotype and comorbidities between patients with COPD and alpha-1-antitrypsin deficiency - An analysis of the COSYCONET cohort. Eur Respir J;48:Suppl.60 PA3111.

74. Vogelmeier C, Fabbri LM, Bell S, Tetzlaff, K, Magnussen, Watz H (2016).Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study. Eur Respir J;48:Suppl.60 PA302.

75. Magnussen H, Arzt M, Andreas S, Plate T, Ribera A, Seoane B, Watz H, Kirsten AM (2016) The effect of aclidinium bromide 400 μg on sleep quality in COPD: A pilot study. Eur Respir J;48:Suppl.60 PA4051.

76. Watz H, Pedersen F, Kirsten A, Nagelschmitz J, Bandel TJ, Schwers S, Rabe KF (2016) Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis. Eur Respir J;48:Suppl.60 PA4088.

77. Watz H, Kirsten A, Pedersen F, Goldmann T, Stellmacher F, Uddin M, Larsson B, Böttcher G, Malmgren A, Kraan M, Rabe KF (2016) Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma. Eur Respir J;48:Suppl.60 PA4892.

78. Alter P, Watz H, Welte T, Gläser S, Schulz H, Bals R, Söhler S, Karch A, Vogelmeier C, Jörres RA (2016) COPD influences on left heart wall stress — An analysis of the COSYCONET cohort. Eur Respir J;48:Suppl.60 PA5029.

79. Richeldi, L, Selman M, Kirsten AM, Wuyts WA, Bernoids K, Stowasser S, Quaresma M, Costabel U (2016) Long-term efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the TOMORROW trial and its open-label extension, ICLAF 2016 JQM 109 suppl1.

80. Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, Disse B, Finnigan H, Asijee GM, Watz H (2017) Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD. Pneumologie 71: P251.

81. Vogelmeier C, Fabbri LM, Bell S, Tetzlaff K, Magnussen H, Watz H (2017) Identification of factors associated with exacerbation risk in severe COPD: multivariate analysis of the WISDOM study. Pneumologie 71: V154.

82. Facius A, Bagul N, Gardiner P, Watz H (2017) Pharmacokinetics of a 4-week up-titration regimen of Roflumilast in the OPTIMIZE study. Am J Respir Crit Care Med 195: A1337.

83. Rabe K, Saetta M, Watz H, Baraldo S, Hanauer G, Göhring UM, Delgadillo J, Roman J, Alagappan V (2017) Reduction in airway eosinophils in patients with COPD treated with Roflumilast for 16 weeks: a double-blind, parallel-group, randomized, placebo-controlled biopsy trial. Am J Respir Crit Care Med 195: A7569.

84. Hessel EM, Hamblin JN, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise C, Galinanes-Garcia L, Watz H, Kirsten A, Fuhr R, Cahn A (2017) Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI13Kδ inhibitor under development for the treatment of COPD. Am J Respir Crit Care Med 195: A7570.

85. Watz H, Troosters T, Beeh KM, Garcia Aymerich J, Paggiaro P, Molins E, Notari M, Jarreta D, Garcia Gil E (2017) Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD. Am J Respir Crit Care Med 195: A3593.

86. Maleki-Yazdi MR, Watz H, Bothner U, Tetzlaff K, Trampisch M, McGarvey L (2017) A comprehensive assessment of the safety profile of Olodaterol in the Respimat® device versus Formoterol for maintenance treatment of COPD. Am J Respir Crit Care Med 195: A3597.

87. Janciauskiene S, Watz H, Holz O, Magnussen H, Olejnicka B, Welte T, Rabe KF, Waschki B (2017) Plasminogen activator inhibitor-1 is elevated in patients with COPD independently of metabolic and cardiosvascular function. Am J Respir Crit Care Med 195: A3627.

88. Pedersen F, Waschki B, Marwitz S, Goldmann T, Kirsten A, Rabe KF, Malmgren A, Richter K, Uddin M, Watz H (2017) The chemokine receptor CXCR2 regulates formation of neutrophil extracellular traps in COPD patients. Am J Respir Crit Care Med 195: A6293.

89. Kahnert K, Lucke T, Biertz F, Lechner A, Alter P, Bals R, Watz H, Behr J, Holle R, Huber RM, Karrasch S, Stubbe B, Wacker M, Sohler S, Wouters EFM, Vogelmeier C, Jorres R (2017) Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Am J Respir Crit Care Med 195: A6492.

90. Bahmer T, Kirsten A, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H (2017) Prognosis and longitudinal changes of physical activity in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 195: A7006.